IL270285B2 - Diagnostic advanced glycation end-product antibodies - Google Patents

Diagnostic advanced glycation end-product antibodies

Info

Publication number
IL270285B2
IL270285B2 IL270285A IL27028519A IL270285B2 IL 270285 B2 IL270285 B2 IL 270285B2 IL 270285 A IL270285 A IL 270285A IL 27028519 A IL27028519 A IL 27028519A IL 270285 B2 IL270285 B2 IL 270285B2
Authority
IL
Israel
Prior art keywords
age
cells
sample
patient
disease
Prior art date
Application number
IL270285A
Other languages
English (en)
Hebrew (he)
Other versions
IL270285A (en
IL270285B1 (en
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of IL270285A publication Critical patent/IL270285A/en
Publication of IL270285B1 publication Critical patent/IL270285B1/en
Publication of IL270285B2 publication Critical patent/IL270285B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL270285A 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies IL270285B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US201762610003P 2017-12-22 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Publications (3)

Publication Number Publication Date
IL270285A IL270285A (en) 2019-12-31
IL270285B1 IL270285B1 (en) 2025-02-01
IL270285B2 true IL270285B2 (en) 2025-06-01

Family

ID=62223287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270285A IL270285B2 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Country Status (9)

Country Link
US (1) US20200150131A1 (https=)
EP (1) EP3619540A1 (https=)
JP (2) JP2020521117A (https=)
KR (2) KR20240006702A (https=)
CN (1) CN110832327A (https=)
AU (1) AU2018261622A1 (https=)
CA (1) CA3062082A1 (https=)
IL (1) IL270285B2 (https=)
WO (1) WO2018204679A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3826670A1 (en) * 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
WO2021113152A1 (en) * 2019-12-02 2021-06-10 Viome, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
US20240329058A1 (en) * 2021-04-09 2024-10-03 Gachon University Of Industry-Academic Cooperation Foundation Biomarker for neurodegenerative diseases comprising glycotoxin, specific protein bound to glycotoxin, or glycotoxin-specific protein complex
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
EP2582293B1 (en) * 2010-06-18 2016-04-20 DiagnOptics Holding B.V. Method and apparatus for determining an autofluorescence value of skin tissue.
AU2015211021B2 (en) * 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10639288B2 (en) * 2014-09-12 2020-05-05 The Procter & Gamble Company Anti-aging skin care compositions and regimens
US10358502B2 (en) * 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
WO2010005531A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2012047629A2 (en) * 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL270285A (en) 2019-12-31
EP3619540A1 (en) 2020-03-11
CN110832327A (zh) 2020-02-21
KR20200003067A (ko) 2020-01-08
JP2023098996A (ja) 2023-07-11
JP2020521117A (ja) 2020-07-16
RU2019139256A (ru) 2021-06-07
RU2019139256A3 (https=) 2022-01-18
KR20240006702A (ko) 2024-01-15
WO2018204679A1 (en) 2018-11-08
AU2018261622A1 (en) 2019-12-12
IL270285B1 (en) 2025-02-01
US20200150131A1 (en) 2020-05-14
CA3062082A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
IL270285B2 (en) Diagnostic advanced glycation end-product antibodies
US11833202B2 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
US20210253739A1 (en) Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells
IL281714B2 (en) Methods for increasing the effectiveness of FOLR1 cancer therapy
EP3742167A1 (en) Composition for screening ongoing progress of alzheimer's disease by using beta amyloid oligomer in nasal discharge specimen and method for screening ongoing progress of alzheimer's disease by using same
JP6890581B2 (ja) Ｃｄ３７の検出のための抗体およびアッセイ
IL292176A (en) Humanized antibody and method for using it
Yu et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety
IL323443A (en) ceacam5 mRNA testing for selecting patients for cancer treatment
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
WO2024090571A1 (ja) Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬
Li et al. Acid sphingomyelinase-ceramide induced vascular injury determines colorectal cancer stem cell fate
JP7762937B2 (ja) 膵臓がんの診断補助方法及び膵臓がん治療用医薬組成物
US12459998B2 (en) Alpha-synuclein binding antibodies, or antigen binding portions thereof
HK40081546A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis